As of Nov 19, 2026, 2 of 2 active firms rate MCRB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MCRB EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect Seres Therapeutics Inc to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-4.81, growing to $-1.95 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $2.0M, rising to $422.0K next year.
Top analysts covering Seres Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MCRB.
#1
Keay Nakae
Chardan Capital · Rank #130
Neutral
$6.00+321.1% to target
Overall win rate
41%
+ Follow
#2
Edward Tenthoff
Piper Sandler · Rank #460
Neutral
$20.00+1303.5% to target
Overall win rate
29%
+ Follow
#3
John Newman
Canaccord Genuity · Rank #538
Buy
$22.00+1443.9% to target
Overall win rate
31%
+ Follow
#4
MK
Matthew Keller
HC Wainwright & Co.
Buy
$12.00+742.1% to target
Coverage
—
+ Follow
#5
Joseph Thome
TD Cowen
Buy
No targeton MCRB
Coverage
—
+ Follow
MCRB stock forecast FAQ
What is MCRB's average 12-month price target?+
The 2 active firms with a live target average $17.00 for Seres Therapeutics Inc over the next 12 months, ranging from a $22.00 high to a $12.00 low, as of Nov 19, 2026.
Is MCRB stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MCRB?+
The Street-high target is $22.00 (Canaccord Genuity), and the Street-low is $12.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $17.00.
How many active Wall Street firms cover MCRB?+
2 active firms have a recognized rating on Seres Therapeutics Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MCRB?+
Among analysts who currently cover MCRB, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Neutral with a $6.00 target.
What is Seres Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at $-4.81, rising to $-1.95 the following year.
How much revenue is Seres Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $2.0M, growing to $422.0K next year.
Have analysts been upgrading or downgrading MCRB lately?+
As of Nov 19, 2026, 2 of 2 active firms rate MCRB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MCRB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.